Search

Mitochondrial dysfunction is currently acknowledged as a central pathomechanism of most common diseases of the 21st century. Recently, the assessment of the bioenergetic profile of human peripheral blood cells has emerged as a novel research field with potential applications in the development of disease biomarkers. In particular, platelets have been successfully used for the ex vivo analysis of mitochondrial respiratory function in several acute and chronic pathologies. An increasing number of studies support the idea that evaluation of the bioenergetic function in circulating platelets may represent the peripheral signature of mitochondrial dysfunction in metabolically active tissues (brain, heart, liver, skeletal muscle). Accordingly, impairment of mitochondrial respiration in peripheral platelets might have potential clinical applicability as a diagnostic and prognostic tool as well as a biomarker in treatment monitoring. The aim of this minireview is to summarize current information in the field of platelet mitochondrial dysfunction in both acute and chronic diseases. [ABSTRACT FROM AUTHOR]

Modulation of mitochondrial function in the settings of ischemia/reperfusion (I/R) injury represents a major therapeutic target of pharmacological agents able to reduce the cell death at reperfusion. The aim of this study was to compare the effects of acute administration of magnesium orotate (MO), MgCl2, orotic acid (OA) with those elicited by the classic mitochondrial permeability transition pore (mPTP) desensitizer, cyclosporine A (CsA) in two experimental settings. The pharmacological agents were administered: i) at reoxygenation in neonatal cardiomyocytes subjected to 4 hours simulated ischemia followed by 2 hours reoxygenation with the assessment of cell viability and reactive oxygen species (ROS) generation, and ii) at reperfusion in isolated rat hearts subjected to 30 min of global ischemia and 120 min of reperfusion. In the latter model myocardial functional recovery (at 30 min of reperfusion) and infarct size (at 120 min of reperfusion) were assessed. In a separate group of animals, mitochondria were isolated at 15 min of reperfusion after global ischemia, and mitochondrial respiration, ROS production (Amplex Red) and calcium retention capacity were assessed. Acute administration of 5 mM MO, MgCl2, OA or 1 μM CsA in neonatal cardiomyocytes subjected to simulated ischemia/reoxygenation enhanced cell survival; these protective effects were not associated with changes in ROS production during reoxygenation. During the postischemic reperfusion in rat hearts and isolated mitochondria, respectively, MO, MgCl2 (5 mM both) and CsA (0.2 μmol/L), but not OA: (i) induced an important recovery of left ventricular end-diastolic pressure (LVDP), and decreased infarct size vs. controls, and (ii) protected against loss of outer mitochondrial membrane integrity and subsequent deficits in electron transport and also inhibited the calcium triggered-mPTP opening. In particular, the effects of MO were comparable to the ones elicited by CsA. In conclusion, acute administration of magnesium orotate in high concentration during the postischemic reperfusion is associated with cardioprotective effects via modulation of mitochondria functions. [ABSTRACT FROM AUTHOR]